Liu Zhuyun, Wu Xiaoping, Dai Kun, Li Renkai, Zhang Jinming, Sheng Dekuan, Lee Simon Ming-Yuen, Leung George Pak-Heng, Zhou Guo-Chun, Li Jingjing
School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, China; School of Pharmacy, Taizhou Polytechnic College, Taizhou, Jiangsu, China.
Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong SAR, China.
Phytomedicine. 2022 Jan;94:153824. doi: 10.1016/j.phymed.2021.153824. Epub 2021 Oct 24.
The anti-cancer activity of andrographolide (Andro) has been extensively demonstrated in recent years. It is supposed that modifying the chemical structure of Andro can improve its efficacy and reduce its toxicity.
In this study, the anti-cancer effect of a 14β-(2'-chlorophenoxy) derivative of andrographolide known as AGS-30 was investigated, and its underlying mechanisms were also explored.
STUDY DESIGN/METHODS: Different cancer cells were used to evaluate and compare the in vitro anti-cancer effects of Andro and AGS-30. Human colon cancer cells HT-29 and HCT-116 were used to study the underlying anti-cancer mechanisms of AGS-30. HT-29 cells xenografted in nude mouse model was used to compare the in vivo anti-tumour efficacies of Andro and AGS-30.
In vitro studies showed that AGS-30 possessed an anti-cancer effect by inhibiting the viability, colony formation and migration of cancer cells. It significantly induced the generation of reactive oxygen species (ROS), caused the loss of mitochondrial membrane potential and triggered the apoptosis in colon cancer cells. These effects of AGS-30 were more potent than those of Andro. In addition, the expression levels of proteins associated with apoptosis, including phospho-JNK1/2 as well as cleaved caspase 9, caspase 3, and poly(ADP ribose) polymerase, were elevated in AGS-30-treated colon cancer cells. Moreover, these elevated levels of the proteins were inhibited by the antioxidant N-acetylcysteine and the JNK inhibitor SP600125, suggesting the involvement of ROS/JNK-dependent mechanisms in AGS-30-induced apoptosis. The in vitro anti-cancer effect could be reproduced in an HT-29 colon cancer cell xenografted nude mouse model.
The anti-cancer effect of AGS-30 is stronger than that of Andro. AGS-30 induces apoptosis of colon cancer cells through ROS/JNK-dependent pathway. Our findings may provide insights for the future development of derivatives of Andro as novel chemotherapeutic agents.
近年来,穿心莲内酯(Andro)的抗癌活性已得到广泛证实。人们认为,修饰穿心莲内酯的化学结构可以提高其疗效并降低其毒性。
本研究考察了穿心莲内酯的14β-(2'-氯苯氧基)衍生物AGS-30的抗癌作用,并探讨了其潜在机制。
研究设计/方法:使用不同的癌细胞来评估和比较穿心莲内酯和AGS-30的体外抗癌效果。利用人结肠癌细胞HT-29和HCT-116研究AGS-30潜在的抗癌机制。采用HT-29细胞异种移植裸鼠模型比较穿心莲内酯和AGS-30的体内抗肿瘤疗效。
体外研究表明,AGS-30通过抑制癌细胞的活力、集落形成和迁移发挥抗癌作用。它显著诱导活性氧(ROS)的产生,导致线粒体膜电位丧失,并触发结肠癌细胞凋亡。AGS-30的这些作用比穿心莲内酯更强。此外,在AGS-30处理的结肠癌细胞中,与凋亡相关的蛋白质表达水平升高,包括磷酸化JNK1/2以及裂解的半胱天冬酶9、半胱天冬酶3和聚(ADP核糖)聚合酶。此外,抗氧化剂N-乙酰半胱氨酸和JNK抑制剂SP600125抑制了这些蛋白质水平的升高,表明ROS/JNK依赖性机制参与了AGS-30诱导的凋亡。体外抗癌作用可在HT-29结肠癌细胞异种移植裸鼠模型中重现。
AGS-30的抗癌作用强于穿心莲内酯。AGS-30通过ROS/JNK依赖性途径诱导结肠癌细胞凋亡。我们的研究结果可能为穿心莲内酯衍生物作为新型化疗药物的未来开发提供思路。